CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Korro Bio, Inc. (KRRO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Korro Bio, Inc. (KRRO)

Pharmaceutical Preparations · market cap $146M · as of 2026-11-02

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-15 (est.)
Phase 2
Pipeline
2
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Korro Bio (KRRO) is a clinical-stage company with a ~$210M market cap (~14.7M shares at ~$14.23). Its two disclosed programs in our data are KRRO-110, a Phase 2 asset for Alpha-1 Antitrypsin Deficiency (AATD), and KRRO-121, a Phase 2 asset for inborn Urea Cycle Disorders (UCD). The near-term setup centers on an estimated mid-December 2026 Phase 2 readout for KRRO-110 in AATD, preceded by earnings around November 11. Our data shows reported cash of only $24.9M against a 2025 net loss of $117M.
The catalyst path
  • 2026-12-15 (est.)Phase 2 · KRRO-110imp 7/10
  • 2027-08-15 (est.)Phase 2 · KRRO-121imp 7/10
Pipeline
AssetPhaseIndication
KRRO-110Phase 2Alpha-1 Anti-trypsin Deficiency
KRRO-121Phase 2Urea Cycle Disorders, Inborn
Price & technical context
3-month
-0.3%
6-month
+32.2%
12-month
+102.8%
52-wk range
$5.28–$16.62
vs 50-day MA
+11.0%
vs 200-day MA
+8.3%
Realized vol
86.0%
Max drawdown
-93.0%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for KRRO (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.